This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Asensus Surgical Beheer

Beheer criteriumcontroles 3/4

De CEO Asensus Surgical is Anthony Fernando, benoemd in Nov2019, heeft een ambtstermijn van 4.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.11M, bestaande uit 23.7% salaris en 76.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.81% van de aandelen van het bedrijf, ter waarde $ 764.99K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 11.6 jaar.

Belangrijke informatie

Anthony Fernando

Algemeen directeur

US$2.1m

Totale compensatie

Percentage CEO-salaris	23.7%
Dienstverband CEO	4.8yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	11.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Anthony Fernando's beloning veranderd ten opzichte van Asensus Surgical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$84m
Mar 31 2024	n/a	n/a	-US$79m
Dec 31 2023	US$2m	US$500k	-US$78m
Sep 30 2023	n/a	n/a	-US$79m
Jun 30 2023	n/a	n/a	-US$80m
Mar 31 2023	n/a	n/a	-US$79m
Dec 31 2022	US$2m	US$440k	-US$76m
Sep 30 2022	n/a	n/a	-US$74m
Jun 30 2022	n/a	n/a	-US$71m
Mar 31 2022	n/a	n/a	-US$64m
Dec 31 2021	US$7m	US$440k	-US$62m
Sep 30 2021	n/a	n/a	-US$60m
Jun 30 2021	n/a	n/a	-US$59m
Mar 31 2021	n/a	n/a	-US$60m
Dec 31 2020	US$3m	US$430k	-US$60m
Sep 30 2020	n/a	n/a	-US$60m
Jun 30 2020	n/a	n/a	-US$143m
Mar 31 2020	n/a	n/a	-US$149m
Dec 31 2019	US$2m	US$392k	-US$154m
Sep 30 2019	n/a	n/a	-US$147m
Jun 30 2019	n/a	n/a	-US$69m
Mar 31 2019	n/a	n/a	-US$83m
Dec 31 2018	US$2m	US$340k	-US$62m
Sep 30 2018	n/a	n/a	-US$131m
Jun 30 2018	n/a	n/a	-US$150m
Mar 31 2018	n/a	n/a	-US$130m
Dec 31 2017	US$1m	US$309k	-US$145m

Compensatie versus markt: De totale vergoeding ($USD 2.11M ) Anthony } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 654.40K ).

Compensatie versus inkomsten: De vergoeding van Anthony is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Anthony Fernando (52 yo)

4.8yrs

Tenure

US$2,106,498

Compensatie

Mr. Anthony Fernando has been President and Chief Executive Officer and Director at Asensus Surgical, Inc. (formerly known as TransEnterix, Inc.) since November 8, 2019 and served as Chief Operating Office...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Anthony Fernando	President	4.8yrs	US$2.11m	0.81% $ 765.0k
Shameze Rampertab	Executive VP & CFO	4yrs	US$1.03m	0.15% $ 144.8k
Joshua Weingard	Chief Legal Officer & Secretary	10.9yrs	geen gegevens	geen gegevens
Ethan Loiselle	Vice President of Global Marketing	1.5yrs	geen gegevens	geen gegevens
Ravi Kommineni	Head of Global Quality & Regulatory	1.5yrs	geen gegevens	geen gegevens
Motti Frimer	Vice President of R&D	less than a year	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ASXC wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Anthony Fernando	President	4.8yrs	US$2.11m	0.81% $ 765.0k
William Starling	Independent Director	11.6yrs	US$90.98k	0.019% $ 18.4k
Richard Pfenniger	Independent Director	19.6yrs	US$101.20k	0.069% $ 65.9k
David Milne	Independent Chairman	11.6yrs	US$151.98k	0.23% $ 215.7k
Steve Eubanks	Member of Advisory Board	no data	geen gegevens	geen gegevens
David Rattner	Member of Advisory Board	no data	geen gegevens	geen gegevens
Paresh Shah	Member of Advisory Board	no data	geen gegevens	geen gegevens
W. Melvin	Member of Advisory Board	no data	geen gegevens	geen gegevens
David Albala	Member of Advisory Board	no data	geen gegevens	geen gegevens
Jose Martinez	Member of Advisory Board	no data	geen gegevens	geen gegevens
Aurora Pryor	Member of Advisory Board	no data	geen gegevens	geen gegevens
Craig Sobolewski	Member of Advisory Board	no data	geen gegevens	geen gegevens

11.6yrs

Gemiddelde duur

65.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ASXC zijn ervaren en ervaren (gemiddelde ambtstermijn van 11.6 jaar).

This company has been acquired

Asensus Surgical Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

President exercised options and sold US$131k worth of stock

President exercised options and sold US$406k worth of stock

Insufficient new directors

Asensus Surgical, Inc., Annual General Meeting, Jun 14, 2022

Recent updates

Asensus Surgical, Inc.(NYSEAM:ASXC) dropped from S&P TMI Index

KARL STORZ Endoscopy-America, Inc. completed the acquisition of Asensus Surgical, Inc. (NYSEAM:ASXC).

New major risk - Negative shareholders equity

Asensus Surgical, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in Urology

New major risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 20%

Asensus Surgical, Inc. to Report Q1, 2024 Results on May 14, 2024

KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. (NYSEAM:ASXC) for $100 million.

Full year 2023 earnings: EPS exceeds analyst expectations

Asensus Surgical, Inc. to Report Q4, 2023 Results on Mar 21, 2024

President exercised options and sold US$131k worth of stock

Consensus revenue estimates increase by 10%

Asensus Surgical, Inc. Provides Unaudited Earnings Guidance for the Quarter and Full Year Ending on December 31, 2023

Asensus Surgical, Inc. Develops the LUNA Surgical System

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Asensus Surgical, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Asensus Surgical, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New minor risk - Share price stability

Consensus EPS estimates fall by 23%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 34%

Price target decreased by 21% to US$1.75

Full year 2022 earnings: EPS exceeds analyst expectations

President exercised options and sold US$406k worth of stock

Asensus Surgical, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Insufficient new directors

Consensus revenue estimates fall by 17%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$2.25

Asensus Surgical, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Asensus Surgical, Inc. Announces Impairment Charges for Three Months Ended June 30, 2022

Asensus Surgical, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Asensus Surgical, Inc. to Showcase the Senhance Surgical System and Performance-Guided Surgery in Upcoming Society of Robotic and Digital Surgery Conference

Asensus Surgical, Inc., Annual General Meeting, Jun 14, 2022

Asensus Surgical, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Asensus Surgical, Inc. Announces Purchase of Senhance Robotic System by Loginov Moscow Clinical Scientific Center

Asensus Surgical Receives FDA 510(k) Clearance for Expansion of Machine Vision Capabilities

Asensus Surgical, Inc. to Report Q4, 2020 Results on Mar 11, 2021

Asensus Surgical Announces FDA Clearance in General Surgery

TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $69.249999 million.

TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $31.25 million.

TransEnterix, Inc. Announces Southern Surgical Hospital to Initiate a Senhance Digital Laparoscopic Program

TransEnterix Announces Approval of Senhance Surgical System in Russian Federation

Transenterix, Inc. Does Not Provide Forward-Looking Guidance

TransEnterix, Inc. to Report Q3, 2020 Results on Nov 05, 2020

TransEnterix, Inc. Announces First Pediatric Surgical Cases with Senhance® Surgical System

TransEnterix Announces Toshima Hospital in Japan to Initiate A Senhance® Digital Laparoscopy Program

Transenterix, Inc. Not Provide Revenue Guidance

TransEnterix, Inc. Contemplates Bankruptcy

TransEnterix, Inc. to Report Q2, 2020 Results on Aug 05, 2020

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Growth Index

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2000 Dynamic Index

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Value Index

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2500 Growth Index

TransEnterix, Inc.(AMEX:TRXC) dropped from S&P Global BMI Index

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd